Literature DB >> 15748535

ACE inhibitors in patients with vascular disease: should the PEACE trial change medical practice?

Robert M Carey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15748535     DOI： 10.1007/s11906-005-0084-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  11 in total

1.  Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation.

Authors:  D Y Li; H J Chen; J L Mehta
Journal:  Cardiovasc Res       Date:  2001-10       Impact factor: 10.787

Review 2.  The importance of reaching lipid targets: statins and the prevention of atherosclerosis.

Authors:  P Schwandt
Journal:  Int J Clin Pract       Date:  2003-06       Impact factor: 2.503

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  ACE inhibitors for patients with vascular disease without left ventricular dysfunction--may they rest in PEACE?

Authors:  Bertram Pitt
Journal:  N Engl J Med       Date:  2004-11-07       Impact factor: 91.245

5.  Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation.

Authors:  D Y Li; Y C Zhang; M I Philips; T Sawamura; J L Mehta
Journal:  Circ Res       Date:  1999-05-14       Impact factor: 17.367

6.  Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB.

Authors:  D Li; T Saldeen; F Romeo; J L Mehta
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

7.  Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.

Authors:  Jiawei Chen; Dayuan Li; Robert F Schaefer; Jawahar L Mehta
Journal:  J Cardiovasc Pharmacol       Date:  2004-10       Impact factor: 3.105

Review 8.  Pleiotropic effects of HMG-CoA reductase inhibitors.

Authors:  Thomas M A Bocan
Journal:  Curr Opin Investig Drugs       Date:  2002-09

9.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 10.  Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease.

Authors:  Balkrishna M Singh; Jawahar L Mehta
Journal:  Arch Intern Med       Date:  2003-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.